Key facts
- Zydus Lifesciences has completed the acquisition of Assertio Holdings for $166.4 million.
- The acquisition was carried out through Zydus' wholly-owned subsidiary, Zara Merger Sub Inc.
- Assertio Holdings is now a wholly-owned subsidiary of Zydus Lifesciences.
- Assertio's shares are no longer traded on the Nasdaq Global Market.
Zydus Lifesciences Ltd announced on Tuesday that it has successfully completed the acquisition of US-based pharmaceutical company Assertio Holdings Inc for $166.4 million. The transaction was executed through Zydus' wholly-owned subsidiary, Zara Merger Sub Inc, which made a cash tender offer for all outstanding shares of Assertio's common stock.